// Hongwei Xia 1,* , Qingjuan Chen 2,3,* , Ying Chen 2 , Xiaojun Ge 1 , Weibing Leng 2 , Qiulin Tang 1 , Ming Ren 2 , Liang Chen 1 , Dandan Yuan 2 , Yucheng Zhang 1 , Ming Liu 2 , Qiyong Gong 4 and Feng Bi 1,2 1 Laboratory of Signal Transduction & Molecular Targeted Therapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan Province, China 2 Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China 3 Department of Medical Oncology, Xian Yang Central Hospital, Xian Yang City, Shanxi Province, China 4 Department of Radiology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China * These authors have contributed equally to this work Correspondence to: Feng Bi, email: // Keywords : long non-coding RNA, MALAT1, gastric cancer, metastasis, miR-122 Received : April 29, 2016 Accepted : May 29, 2016 Published : July 29, 2016 Abstract The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is frequently over-expressed and serves as a prognostic marker in human cancers. However, little is known about the role of MALAT1 in gastric cancer. Here, we reported that the tissue and plasma MALAT1 levels were significantly higher in gastric cancer patients with distant metastasis (P<0.01) than patients without distant metastasis and the healthy controls. In addition, high levels of plasma MALAT1 independently correlated to a poor prognosis for gastric cancer patients (hazard ratio, 0.242; 95% CI, 0.154-0.836; P=0.036; Cox regression analysis). Functional studies revealed that knockdown of MALAT1 could inhibit cell proliferation, cell cycle progression, migration and invasion, and promote apoptosis in gastric cancer cells. Furthermore, the miR-122-IGF-1R signaling correlated with the dysregulated MALAT1 expression in gastric cancer. These data suggest that MALAT1 could function as an oncogene in gastric cancer, and high MALAT1 level could serve as a potential biomarker for the distant metastasis of gastric cancer.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: